Clinical trial
A Phase Ⅲ, Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of Combination Treatment of Motixafortide and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma
NCT06514508 is registered in ClinicalTrials.gov with Guangzhou Gloria Biosciences Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅲ, Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of Combination Treatment of Motixafortide and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma
- Lead sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 1, 2025
- Completion date
- May 31, 2027
- Enrollment
- 60 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.